Positioning novel biologicals in CKD-mineral and bone disorders.

about

Positioning novel biologicals in CKD-mineral and bone disorders.

Item

http://www.wikidata.org/entity/Q39328170

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Positioning novel biologicals in CKD-mineral and bone disorders.

@en

Positioning novel biologicals in CKD-mineral and bone disorders.

@nl

type

Item

label

Positioning novel biologicals in CKD-mineral and bone disorders.

@en

Positioning novel biologicals in CKD-mineral and bone disorders.

@nl

prefLabel

Positioning novel biologicals in CKD-mineral and bone disorders.

@en

Positioning novel biologicals in CKD-mineral and bone disorders.

@nl

P1476

Positioning novel biologicals in CKD-mineral and bone disorders

@en

P2093

Adrian Covic

http://www.w3.org/2001/XMLSchema#string

Lida Tartaglione

http://www.w3.org/2001/XMLSchema#string

Maria Luisa Muci

http://www.w3.org/2001/XMLSchema#string

Marzia Pasquali

http://www.w3.org/2001/XMLSchema#string

P2860

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

Bone resorption by osteoclasts

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

P2888

s40620-017-0410-1

P304

689-699

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40620-017-0410-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sandro Mazzaferro

Silverio Rotondi

P577

2017-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28540603

http://www.w3.org/2001/XMLSchema#string